Last reviewed · How we verify
MCLA-128
At a glance
| Generic name | MCLA-128 |
|---|---|
| Also known as | Zenocutuzumab |
| Sponsor | Merus B.V. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers (PHASE2)
- Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) (PHASE2)
- MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCLA-128 CI brief — competitive landscape report
- MCLA-128 updates RSS · CI watch RSS
- Merus B.V. portfolio CI